Optimized PLGA nanoparticle platform for orally dosed trans-resveratrol with enhanced bioavailability potential

Expert Opinion on Drug Delivery

Volumn 11, Issue 5, 2014, Pages 647-659

  Singh, Gurinder ^a   Pai, Roopa S ^a  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

Author keywords

Central composite design; Enterohepatic recirculation; in situ single pass intestinal perfusion; in vitro in vivo correlation; Pharmacokinetic; trans resveratrol

Indexed keywords

POLYGLACTIN; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENCY; ENTEROHEPATIC CIRCULATION; IN VIVO STUDY; INTESTINE PERFUSION; MALE; NONHUMAN; PEYER PATCH; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; EMULSIFYING AGENTS; INTESTINAL ABSORPTION; LACTIC ACID; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; RATS, WISTAR; STILBENES; TISSUE DISTRIBUTION;

EID: 84899087299     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.890588     Document Type: Article

References (44)

1. Kim S, Ng WK, Dong Y, et al. Preparation and physicochemical characterization of trans-resveratrol nanoparticles by temperature-controlled antisolvent precipitation. J Food Eng 2012;108:37-42
2. Singh G, Pai RS, Pandit V. Development and validation of a HPLC method for the determination of transresveratrol in spiked human plasma. J Adv Pharm Technol Res 2012;3:130-5
3. Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: what formulation solutions to bioavailability limitations. J Control Release 2012;158:182-93
4. Ortuno J, Covas MI, Farre M, et al. Matrix effects on the bioavailability of resveratrol in humans. Food Chem 2010;120:1123-30
5. Kristl J, Teskac K, Caddeo C, et al. Improvement of cellular stress response on resveratrol in liposomes. Eur J Pharm Biopharm 2009;73:253-9
6. Singh G, Pai RS, Pandit V. In vivo pharmacokinetic applicability of a simple and validated HPLC method for orally administered trans-resveratrol loaded polymeric nanoparticles to rats. J Pharm Investig 2013. [Epub ahead of print]
7. Das S, Ng KY. Quantification of transresveratrol in rat plasma by a simple and sensitive high performance liquid chromatography method and its application in pre-clinical study. J Liq Chromatogr Relat Technol 2011;34:1399-414
8. Amiot MJ, Romier B, Dao TM, et al. Optimization of trans-resveratrol bioavailability for human therapy. Biochimie 2013;95:1233-8
9. Gambini J, Lopez-Grueso R, Olaso-Gonza'lez G, et al. Resveratrol: distribution, properties and perspectives. Rev Esp Geriatr Gerontol 2013;48:79-88
10. Sale S, Verschoyle RD, Boocock D, et al. Pharmacokinetics inmice and growthinhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans-3,4,5,4¢- tetramethoxystilbene. Br J Cancer 2004;90:736-44 (Pubitemid 38297218)
11. Yeo SC, Ho PC, Lin HS. Pharmacokinetics of pterostilbene in sprague-dawley rats: the impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. Mol Nutr Food Res 2013;57:1015-25
12. Hung CF, Chen JK, Liao MH, et al. Development and evaluation of emulsion-liposome blends for resveratrol delivery. J Nanosci Nanotechnol 2006;6:2950-8
13. Wegiel LA, Mauer LJ, Edgar KJ, Taylor LS. Crystallization of amorphous solid dispersions of resveratrol during preparation and storage-impact of different polymers. J Pharm Sci 2013;102:171-84
14. Troche-Pesqueira E, Perez-Juste I, Navarro-Vazquez A, Magdalena Cid M. A beta-cyclodextrin-resveratrol inclusion complex and the role of geometrical and electronic effects on its electronic induced circular dichroism. RSC Adv 2013;3:10242-50
15. Nam JB, Ryu JH, Kim JW, et al. Stabilization of resveratrol immobilized in monodisperse cyano-functionalized porous polymeric microspheres. Polymer (Guildf) 2005;46:8956-63
16. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine 2008;4:273-82
17. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008;5:496-504
18. Kreuter J. Peroral administration of nanoparticles. Adv Drug Deliv Rev 1991;7:71-86
19. Jani P, Halbert GW, Langridge J, Florence AT. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol 1989;41:809-12 (Pubitemid 20112141)
20. Damge C, Michel C, Aprahamian M, et al. Nanocapsules as carriers for oral peptide delivery. J Control Release 1990;13:233-9 (Pubitemid 20313521)
21. Kreuter J. Nanoparticles and microparticles for drug and vaccine delivery. J Anat 1996;189:503-5 (Pubitemid 27011002)
22. Zakeri-Milani P, Valizadeh H, Tajerzadeh H, Islambulchilar Z. The utility of rat jejunal permeability for biopharmaceutics classification system. Drug Dev Ind Pharm 2009;35:1496-502
23. Jeong EJ, Liu Y, Lin H, Hu M. In situ single-pass perfused rat intestinal model for absorption and metabolism. In: Yan Z, Caldwell GW, editors, Optimization in drug discovery, methods in pharmacology and toxicology. Springer protocols, New Jersey; 2004. p. 65-76
24. Singh G, Pai RS, Devi VK. Response surface methodology and process optimization of sustained release pellets using taguchi orthogonal array design and central composite design. J Adv Pharm Technol Res 2012;3:30-40
25. Singh B, Kapil R, Nandi M, Ahuja N. Developing oral drug delivery systems using formulation by design: vital precepts, retrospect and prospects. Expert Opin Drug Deliv 2011;8:1341-60
26. Singh G, Pai RS. Pharmacokinetics and in vivo biodistribution of optimized PLGA nanoparticulate drug delivery system for controlled release of emtricitabine. Drug Deliv 2013. [Epub ahead of print]
27. Quevedo MA, Nieto LE, Brinon MC. P-glycoprotein limits the absorption of the anti-HIV drug zidovudine through rat intestinal segments. Eur J Pharm Sci 2011;43:151-9
28. Lv S, Tang Z, Song W, et al. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy. Acta Biomater 2013;9:9330-42
29. Lu Y, Kim S, Park K. In vitro/in vivo correlation: perspectives on model development. Int J Pharm 2011;418:142-8
30. Q1A(R2), Stability Testing of New Drug Substances and Products, 2003
31. USP, USP 34, NF 29. The United States pharmacopeia and the National formulary. The United States Pharmacopeial Convention, Rockwille, MD; 2011. p. 20852
32. Ho YF, Lai MY, Yu HY, et al. Application of rat in situ single-pass intestinal perfusion in the evaluation of pre systemic extraction of indinavir under different perfusion rates. J Formos Med Assoc 2008;107:37-45
33. Zhao P, Wang H, Yu M, et al. Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation. Eur J Pharm Biopharm 2012;81:248-56
34. Feng S, Huang G. Effects of emulsifiers on the controlled release of paclitaxel (taxol) from nanospheres of biodegradable polymers. J Control Release 2001;71:53-69 (Pubitemid 32195441)
35. Doornbos CA, Haan PD. Optimization techniques in formulation and processing. In: Swarbrick J, Boylan JC, editors, Encyclopedia of pharmaceutical technology. Marcel Dekker, New York; 1995. p. 77-160
36. Fonseca C, Simo?es S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 2002;83:273-86 (Pubitemid 35282471)
37. Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MNV. Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Rel 2007;119:77-85 (Pubitemid 46561546)
38. Marier JF, Vachon P, Gritsas A, et al. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 2002;302:369-73 (Pubitemid 34680460)
39. Singh G, Pai RS. Trans-resveratrol self nano-emulsifying drug delivery systems (SNEDDS) with enhanced bioavailability potential: Optimization, pharmacokinetics and in situ single pass intestinal perfusion (SPIP) studies. Drug Deliv 2014. [Epub ahead of print]
40. Lee J, Lee IH, et al. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J Med Chem 2008;51:6442-9
41. Zhao L, Liu A, Sun M, et al. Enhancement of oral bioavailability of puerarin by polybutylcyanoacrylate nanoparticles. J Nanomater 2011;2011:8, [Article ID 126562], doi:10.1155/2011/126562
42. Zhanga J, Lva H, Jiang K, Gao Y. Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal. Int J Pharm 2011;420:180-8
43. Jiao Y, Ubrich N, Arvier MM, et al. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002;105:230-5 (Pubitemid 34084324)
44. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 2012;64:557-70